Novel dipeptidyl hydroxamic acids that inhibit human and bacterial dipeptidyl peptidase III

Dipeptidyl Peptidase-4 Inhibitor

In the United States, nearly 13% of adults aged 20 years and older have type 2 diabetes mellitus (T2DM), and its prevalence is still increasing (1,2). Microvascular and macrovascular abnormalities are common in patients with T2DM and are related to the severity and duration of hyperglycemia (3–5). Thus, treatment of hyperglycemia is an important way to prevent or delay diabetic vascular complic...

Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancreatitis. Previously, based on a computational analysis of the spatial and electrostatic properties...

Targeting Dipeptidyl Peptidase IV (CD26)

Murine Neutrophil Chemorepellent Dipeptidyl Peptidase IV Is a Human and

Dipeptidyl Peptidase IV and Incident Diabetes

OBJECTIVE Dipeptidyl peptidase IV (DPP-IV) is not only important in beta-cell function but also has proinflammatory actions. We aimed to investigate whether it could act as a link between low-grade chronic inflammation and diabetes. RESEARCH DESIGN AND METHODS Using a case-cohort design, we followed 546 middle-aged individuals who developed diabetes and 538 who did not over approximately 9 ye...